Guan discusses the potential for reducing healthcare costs by re-evaluating the financialization of the industry, particularly through centralized drug price negotiations. He explores the idea of abolishing pharmaceutical patents while suggesting alternative funding mechanisms for drug research, such as government financing and prize incentives. The conversation also touches on the implications of hedge fund strategies that target weak patents, highlighting the complexity and entrepreneurial spirit behind such trades.
